Angiogenesis is essential for tumor development. Assessing the response of tumors to new cytostatic treatments, such as anti-angiogenesis agents, requires functional evaluation of the tumor vasculature, in addition to the traditional measures of tumor size. Magnetic resonance perfusion imaging (MRPI) can provide exogenous and endogenous tracer methods to generate information about tumor vascular characteristics such as permeability, perfusion, and blood volume. As a result, MRPI is a critical tool for investigating the efficacy of new therapies and, specifically, for monitoring tumor response to therapy.
|Original language||English (US)|
|Number of pages||9|
|Issue number||6 SUPPL.|
|State||Published - Jun 1 2003|